tbuckley/cabot-search huggingface dataset:
488P Patient-derived organoids as a tool for modelling localized colorectal cancer
Authors: M.F. Gutierrez Bravo, F. Papaccio, M. Cabeza, C. Martínez-Ciarpaglini, C. Alfaro-Cervello, Z. Garzón-Lloría, A. Ferrer-Martínez, B. García-Micó, V. Gambardella, P. Rentero-Garrido, T. Fleitas, D. Moro-Valdezate, M. Huerta, N. Tarazona, D. Roda, A. Cervantes, J. Castillo
Journal: Annals of Oncology (2020)
1924P Diagnostic demographics of radioiodine-refractory differentiated thyroid cancer (RR-DTC) and usage patterns of local and systemic therapies (ERUDIT study)
Authors: C. López, R.J. Santos, M. Llanos Muñoz, J.A. Vallejo, E. Navarro González, J. Aller Pardo, V. Pubul Núñez, M. Sambo Salas, S. Guadalix Iglesias, G. Crespo, C. Zafon, C. González Blanco, Á.A. Segura Huerta, M. Navarro Martín, J. Santamaría Sandi, P. Gajate Borau, J. Valdivia, M. Gómez Balaguer, L. Orcajo Rincon, J. Rodríguez-Villanueva
Journal: Annals of Oncology (2020)
1574P The cognitive, affective, social and environmental drivers of inappropriate ovarian cancer screening: A survey of women and their clinicians using the theoretical domains framework
Authors: C. Macdonald, D. Mazza, M. Hickey, M. Hunter, L.A. Keogh, S.C. Jones, C. Saunders, S. Nesci, R.L. Milne, S.A. McLachlan, J. Hopper, M. Friedlander, J. Emery, K.A. Phillips
Journal: Annals of Oncology (2020)
Competing Visions for the Future of Health Policy
Authors: Matthew Fiedler
Journal: New England Journal of Medicine (2020)

Interview with Dr. Matthew Fiedler on disagreement about the role of government in health insurance and health care in the United States. (09:47)Download Beyond Covid-19, two other health policy issues are poised to feature prominently in the 2020 U.S. elections: what role government should play in ensuring broad health insurance coverage, and how to cope with the lack of competition in many health care provider markets.
1514P Patient-reported outcomes of early integration palliative care in quality of life and symptom burden in advanced lung cancer – A randomized study
Authors: R. Félix Soares, R. Silva, É. Rodrigues, M. Amaral, M.J. Nabais, T. Cunha Pereira, M. Peixoto, F. Macedo, A.R. Monteiro, F. Pontes, I. Domingues, A.R. Garcia, I. Rêgo, J. Cunha Carvalho, A. Chaves, E. Jesus, Ó. Vilão, G. Sousa
Journal: Annals of Oncology (2020)
709P Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study
Authors: B.A. McGregor, N. Agarwal, C. Suarez, C-K. Tsao, W. Kelly, L. Pagliaro, U.N. Vaishampayan, D. Castellano, Y. Loriot, S. Werneke, D. Curran, T.K. Choueiri, S. Pal
Journal: Annals of Oncology (2020)
734P Kidney manifestations in patients with hereditary leiomyomatosis and renal cell cancer syndrome (LHRCC) in Spain
Authors: A.B. Sanchez, A. Teule, E. Lastra, J. Balmana, L. Robles, J.D.D. García, T. Ramón y Cajal, G. Llort, M. Fonfria, M. Robledo, A. Castillejo, M. Duran, A. Zuñiga, L. Gómez, E. Grau Garcés, A. López, M. Bosquet-Sanz, V. Barberá, J.L. Soto
Journal: Annals of Oncology (2020)
A quick prediction tool for unfavourable outcome in COVID-19 inpatients: Development and internal validation
Authors: Sonsoles Salto-Alejandre, Cristina Roca-Oporto, Guillermo Martín-Gutiérrez, María Dolores Avilés, Carmen Gómez-González, María Dolores Navarro-Amuedo, Julia Praena-Segovia, José Molina, María Paniagua-García, Horacio García-Delgado, Antonio Domínguez-Petit, Jerónimo Pachón, José Miguel Cisneros
Journal: Journal of Infection (2020)
1080MO The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition
Authors: J.M. Versluis, A.M. Hendriks, A. Weppler, L. Brown, K. de Joode, K.P.M. Suijkerbuijk, L. Zimmer, E. Kapiteijn, C. Allayous, D.B. Johnson, A. Hepner, J. Mangana, P. Bhave, Y. Jansen, C. Trojaniello, V. Atkinson, L. Storey, E.G.E. de Vries, C.U. Blank, M. Jalving
Journal: Annals of Oncology (2020)
1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
Authors: M. Reck, A. Spira, B. Besse, J. Wolf, F. Skoulidis, H. Borghaei, K. Goto, K. Park, F. Griesinger, E. Felip, M. Boyer, C.H. Barrios, G. Goss, H. Yang, C. Obiozor, S.S. Ramalingam
Journal: Annals of Oncology (2020)
583P Effect of infusion rate, premedication, and prophylactic peg-filgrastim treatment on the safety of the liposomal formulation of eribulin (E7389-LF): Results from the expansion part of a phase I study
Authors: S. Iwasa, S. Takahashi, M. Hirao, K. Kato, K. Shitara, Y. Sato, T. Hamakawa, H. Horinouchi, M. Tahara, K. Chin, M. Mizutani, T. Suzuki, T. Takase, R. Matsunaga, T. Mukohara
Journal: Annals of Oncology (2020)
1704P COVID-19 mortality in patients receiving anti-cancer therapy in a UK national cancer centre
Authors: A. Wu, C.C.T. Sng, S. Benafif, N. Chopra, M. Galazi, A.J.X. Lee, D. Ottaviani, G.B. Soosaipillai, Y.N.S. Wong, H.M. Shaw
Journal: Annals of Oncology (2020)
79TiP A phase II/III, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer
Authors: D-Y. Oh, F. de Braud, J. Bridgewater, J. Furuse, C-H. Hsu, M. Ikeda, M. Javle, M. Moehler, J.O. Park, L. Shen, C. Yoo, C. Helwig, M. Osada, M. Borad
Journal: Annals of Oncology (2020)
1151P Trends in melanoma mortality in Brazil: A 20-year registry-based study
Authors: G. Nader Marta, R. Ramella Munhoz, M. La Porte Teixeira, B. Cunha Waldvogel, V.P.D. Camargo, M. Nardo, C. Chaul de Lima Barbosa, O. Feher, P.M. Hoff, J.A. Sanches
Journal: Annals of Oncology (2020)
221P Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO
Authors: D. Eiger, Z. Tsourti, R. Caparica, M. Kassapian, S. Napoleone, S. Hultsch, L. Korde, Y. Wang, S. Chumsri, K. Pritchard, M. Untch, M. Bellet Ezquerra, D.D. Rosa, A. Moreno-Aspitia, M. Piccart, U. Dafni, E. de Azambuja
Journal: Annals of Oncology (2020)
1629MO First-line chemotherapy (CT) in advanced well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
Authors: S. Stacchiotti, W. Van der Graaf, H. Doms, R. Sanfilippo, S.I. Marreaud, W. Van Houdt, I. Judson, B. Kasper, S. Litiere, H. Gelderblom
Journal: Annals of Oncology (2020)
1784P Activity of lurbinectedin in second-line SCLC patients candidates for platinum re-challenge
Authors: V. Subbiah, L. Paz-Ares, B. Besse, V. Moreno, K. Zaman, M.A. Sala Gonzalez, J.A. Lopez-Vilarino, C.M. Fernandez, C. Kahatt, M. Siguero, A. Zeaiter, R. Lopez Lopez, S. Ponce Aix, V. Boni, J. Arrondeau, J-P. Delord, M. Martínez-Aguillo, L. Wannesson De Nicola, A. Anton Torres, J.M. Trigo Perez
Journal: Annals of Oncology (2020)
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management
Authors: Ayalew Tefferi, Tiziano Barbui
Journal: American Journal of Hematology (2020)

Abstract Disease overview Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus and risk of leukemic or fibrotic transformation. Diagnosis Bone marrow morphology remains the cornerstone of diagnosis. In addition, the presence of JAK2 mutation is expected in PV while approximately 90% of patients with ET express mutually exclusive JAK2 , CALR or MPL mutations (so called driver mutations). In ET, it is most important to exclude the possibility of prefibrotic myelofibrosis. Survival Median survivals are approximately 15 years for PV and 18 years for ET; the corresponding values for patients age 40 or younger were 37 and 35 years. Certain mutations (mostly spliceosome) and abnormal karyotype might compromise survival in PV and ET. Life‐expectancy in ET is inferior to the control population. Driver mutations have not been shown to affect survival in ET but risk of thrombosis is higher in JAK2 mutated cases. Leukemic transformation rates at 10 years are estimated at &lt;1% for ET and 3% for PV. Thrombosis risk In PV, two risk categories are considered: high (age &gt; 60 years or thrombosis history present) and low (absence of both risk factors). In ET, four risk categories are considered: very low (age ≤ 60 years, no thrombosis history, JAK2 wild‐type), low (same as very low but JAK2 mutation present), intermediate (age &gt; 60 years, no thrombosis history, JAK2 wild‐type) and high (thrombosis history present or age &gt; 60 years with JAK2 mutation). Risk‐adapted therapy The main goal of therapy in both PV and ET is to prevent thrombohemorrhagic complications. All patients with PV require phlebotomy to keep hematocrit below 45% and once‐daily or twice‐daily aspirin (81 mg), in the absence of contraindications. Very low risk ET might not require therapy while aspirin therapy is advised for low risk disease. Cytoreductive therapy is recommended for high‐risk ET and PV, but it is not mandatory for intermediate‐risk ET. First‐line drug of choice for cytoreductive therapy, in both ET and PV, is hydroxyurea and second‐line drugs of choice are interferon‐α and busulfan. We do not recommend treatment with ruxolutinib in PV, unless in the presence of severe and protracted pruritus or marked splenomegaly that is not responding to the aforementioned drugs. New treatment directions Controlled studies are needed to confirm the clinical outcome value of twice‐daily vs once‐daily aspirin dosing and the therapeutic role of pegylated interferons and direct oral anticoagulants.
Art in Endoscopy: “Interstellar wormhole”
Authors: Adrian Săftoiu
Journal: Endoscopy (2020)

This magnified image of the terminal ileum shows a typical pattern of nodular lymphoid hyperplasia in a patient with minimal symptoms and without associated diseases; the digital contrast technology in optical enhancement mode depicts bile in bright red. The image resembles 3 D renderings of sci-fi “wormholes,” speculative structures linking disparate points in spacetime, that are theoretically possible according to a special solution of Einstein’s general relativity equations. More pragmatically, nodular lymphoid hyperplasia represents the occurrence of small nodules (less than 10 mm), located preferentially in the terminal ileum and confirmed by pathology exam. Although often asymptomatic, it can be associated with diffuse pain, chronic diarrhea, or bleeding. It is sometimes associated with other immunodeficiency diseases or infections, as well as celiac disease, being considered a risk factor for intestinal or extraintestinal lymphoma.
378P MGMT status influences prognosis of patients with IDH wild type grade III gliomas
Authors: E. Franceschi, V. Di Nunno, A. Tosoni, L. Gatto, M. Di Battista, S. Minichillo, A. Mura, C. Lamperini, G. Nuvola, M. Sisi, M. Mosca, S. Bartolini, A.A. Brandes
Journal: Annals of Oncology (2020)
1401P Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
Authors: D. Planchard, P-H. Feng, N. Karaseva, S-W. Kim, T.M. Kim, C.K. Lee, A. Poltoratskiy, N. Yanagitani, S. Powar, X. Huang, P. Howarth, P. Jänne, K. Kobayashi
Journal: Annals of Oncology (2020)
275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)
Authors: V. Mueller, E. Paplomata, E.P. Hamilton, A. Zelnak, L. Fehrenbacher, E.H. Jakobsen, E. Curtit, F. Boyle, E.H. Brix, A.J. Brenner, C. Ferrario, M. Munoz-Mateu, T. Arkenau, K.A. Gelmon, D. Cameron, G. Curigliano, K. DeBusk, J. Ramos, X. An, A.M. Wardley
Journal: Annals of Oncology (2020)
Delayed microglial depletion after spinal cord injury reduces chronic inflammation and neurodegeneration in the brain and improves neurological recovery in male mice
Authors: Yun Li, Rodney M. Ritzel, Niaz Khan, Tuoxin Cao, Junyun He, Zhuofan Lei, Jessica J. Matyas, Boris Sabirzhanov, Simon Liu, Hui Li, Bogdan A. Stoica, David J. Loane, Alan I. Faden, Junfang Wu
Journal: Theranostics (2020)

Neuropsychological deficits, including impairments in learning and memory, occur after spinal cord injury (SCI). In experimental SCI models, we and others have reported that such changes reflect sustained microglia activation in the brain that is associated with progressive neurodegeneration. In the present study, we examined the effect of pharmacological depletion of microglia on posttraumatic cognition, depressive-like behavior, and brain pathology after SCI in mice. Methods: Young adult male C57BL/6 mice were subjected to moderate/severe thoracic spinal cord contusion. Microglial depletion was induced with the colony-stimulating factor 1 receptor (CSF1R) antagonist PLX5622 administered starting either 3 weeks before injury or one day post-injury and continuing through 6 weeks after SCI. Neuroinflammation in the injured spinal cord and brain was assessed using flow cytometry and NanoString technology. Neurological function was evaluated using a battery of neurobehavioral tests including motor function, cognition, and depression. Lesion volume and neuronal counts were quantified by unbiased stereology. Results: Flow cytometry analysis demonstrated that PLX5622 pre-treatment significantly reduced the number of microglia, as well as infiltrating monocytes and neutrophils, and decreased reactive oxygen species production in these cells from injured spinal cord at 2-days post-injury. Post-injury PLX5622 treatment reduced both CD45int microglia and CD45hi myeloid counts at 7-days. Following six weeks of PLX5622 treatment, there were substantial changes in the spinal cord and brain transcriptomes, including those involved in neuroinflammation. These alterations were associated with improved neuronal survival in the brain and neurological recovery. Conclusion: These findings indicate that pharmacological microglia-deletion reduces neuroinflammation in the injured spinal cord and brain, improving recovery of cognition, depressive-like behavior, and motor function.
380P Ten-year experience of the Vall d’Hebron Institute of Oncology early drug development unit (VHIO-UITM) treating patients (pts) with primary CNS tumours (pCNS)
Authors: N. Saoudi Gonzalez, M. Vieito Villar, A.B. Azaro Pedrazzoli, I. Braña, A. Garcia-Alvarez, F.J. Ros Montañá, R. Berchel Barcelo, M. Gonzalez, O. Saavedra Santa Gadea, G. Alonso Casal, V. Galvao de Aguiar, A. Hernando-Calvo, N. Ann Worham, M. Sole-Domenech, J. Llavall Sanchez, F. Martinez-Ricarte, E. Martinez Saez, J. Carles, R. Dienstmann, E. Garralda
Journal: Annals of Oncology (2020)
Asthma-associated risk for COVID-19 development
Authors: Chrysanthi Skevaki, Antonina Karsonova, Alexander Karaulov, Min Xie, Harald Renz
Journal: Journal of Allergy and Clinical Immunology (2020)

The newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a pandemic (coronavirus disease 2019 [COVID-19]). It is now well established that certain comorbidities define high-risk patients. They include hypertension, diabetes, and coronary artery disease. In contrast, the context with bronchial asthma is controversial and shows marked regional differences. Because asthma is the most prevalent chronic inflammatory lung disease worldwide and SARS-CoV-2 primarily affects the upper and lower airways leading to marked inflammation, the question arises about the possible clinical and pathophysiological association between asthma and SARS-CoV-2/COVID-19. Here, we analyze the global epidemiology of asthma among patients with COVID-19 and propose the concept that patients suffering from different asthma endotypes (type 2 asthma vs non-type 2 asthma) present with a different risk profile in terms of SARS-CoV-2 infection, development of COVID-19, and progression to severe COVID-19 outcomes. This concept may have important implications for future COVID-19 diagnostics and immune-based therapy developments.
1320P Impact of body mass index (BMI) in non-small cell lung cancer patients treated with anti PD-1 immunotherapy (IO): A retrospective cohort study
Authors: A.C. Bravo, S.L. Lobo-Martins, I. Vendrell, A.B. Mansinho, C. Melo-Alvim, D. Hasmucrai, A.S. Vilariça, P. Alves, E. Teixeira, R. Teixeira de Sousa, C. Bárbara, L. Costa
Journal: Annals of Oncology (2020)
1175P Temozolomide alone or combined with capecitabine for the treatment of metastatic neuroendocrine neoplasia: A “Real World” data analysis
Authors: A. Bongiovanni, C. Liverani, F. Foca, M. Signoretti, F. Pieri, A. Tartaglia, R. Galassi, D. Cavaliere, S. Severi, V. Fausti, G. Di Menna, L. Mercatali, A. De Vita, N. Riva, S. Calpona, G. Miserocchi, C. Spadazzi, T. Ibrahim
Journal: Annals of Oncology (2020)
1221P Surgically resected superior sulcus (SS) non-small cell lung cancer (NSCLC) after induction chemo (C)- and radiotherapy (R): A focus on the immune microenvironment (IM)
Authors: A. Pavan, F. Fortarezza, F. Pezzuto, R. Polverosi, L. Evangelista, S. Frega, L. Bonanno, V. Guarneri, F. Rea, P.F. Conte, F. Calabrese, G. Pasello
Journal: Annals of Oncology (2020)
Abstract #LB-35: Arginine deiminase inhibits interleukin-2-induced hypotension and increases its anticancer activity in renal cell carcinoma
Authors: Young-Jun Shim, Cheol-Yong Yoon, Eun-Ho Kim, Hye-Sook Jeon, Bon-Hong Min
Journal: Cancer Research (2009)

Interleukin-2 (IL-2) is used as an effective immunotherapy to treat metastatic renal cell carcinoma (RCC) in spite of its toxic side effects. Hypotension is the main toxicity of IL-2 therapy, resulting in vasodilation and a decrease in vascular resistance caused by nitric oxide (NO). Thus, it is important to find an agent that blocks IL-2-mediated hypotension without reducing anti-cancer activity of IL-2. In this study, we have investigated whether arginine deiminase (ADI) ameliorates the hypotension associated with IL-2 in RENCA tumor model since ADI inhibited NO production as well as RCC tumor growth in our previous reports (Mol Cells 13: 137, 2002; Int J Cancer 120: 897, 2007). We found that the plasma NO levels of mice injected with high dose of IL-2 (400,000 IU) were significantly increased but co-administration of ADI (5 U) blocked the rise of NO level. In addition, ADI in combination prolonged the survival time while the mice treated with lethal dose of IL-2 were all dead at 4 days after injection, suggesting the feasibility of IL-2 dose escalation. Furthermore, we found that ADI (2.5 U) synergistically inhibited RENCA tumor growth as it was co-administrated with IL-2 (400,000 IU). It was, interestingly, found that the growth of both total splenocytes and natural killer (NK) cells from mice is enhanced after ADI treatment. In conclusion, ADI, in combination with IL-2, blocked IL-2-induced hypotension and the subsequent lethal effect via inhibiting NO production and the enhanced anti-tumor effect of the combined treatment could be due to the increase in proliferation of splenocytes containing NK cells. Taken together, these results suggest that ADI can be a potent new anti-cancer drug on RCC in that RCC is arginine-auxotrophic and the combined treatment with IL-2 exerts synergistic anti-tumor effect, reducing hypotension. This work was supported by MRC program through the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korean Ministry of Education, Science and Technology (MEST) (R13-2003-016-02002-0).  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-35.
551P Phase I study of lurbinectedin in Japanese patients with pretreated advanced tumours: Final results
Authors: S. Takahashi, T. Shimizu, T. Doi, J.A. Lopez-Vilarino, R. Nunez Martin, C. Kahatt, C. Fernandez Teruel, H. Sasamoto, A. Zeaiter
Journal: Annals of Oncology (2020)
Abstract 20477: Cardiorespiratory Fitness, Coronary Artery Calcium and Cardiovascular Disease Events
Authors: Laura F DeFina, Nina B Radford, David Leonard, Carolyn E Barlow, Benjamin Willis, Amit Khera, Benjamin D Levine
Journal: Circulation (2014)

Introduction: Both coronary calcification (CAC) and cardiorespiratory fitness (CRF) are associated with coronary heart disease. We sought to evaluate the separate contribution of each of these parameters to cardiovascular disease (CVD) events. Methods: We studied 8505 men and 3479 women with a preventive health examination which included measurement of CRF and CAC between 1997 and 2007. There were 452 cases of incident CVD (non-fatal myocardial infarction, non-fatal atherosclerotic stroke, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, stent, or CVD death) during an average follow-up of 8.3 years. CVD incidence was estimated using an accelerated failure time model adjusted for age, CRF, CAC and smoking. Age and cardiorespiratory fitness were expanded in a cubic spline basis, allowing the model to detect nonlinear accelerations associated with these covariates. In addition, a proportional hazards regression model was fit to the same outcome with the same covariates. Results: ...
1938P Profiling of circulating tumour DNA for treatment selection in patients with advanced and refractory carcinoma: A prospective, two-stage phase II individualized cancer treatment trial
Authors: A. Gerger, J.M. Riedl, S. Perakis, G. Pregartner, L. Scheipner, F. Posch, K. Groller, K. Kashofer, S.W. Jahn, T. Bauernhofer, M. Pichler, H. Stöger, A. Berghold, G. Höfler, M. Speicher, E. Heitzer
Journal: Annals of Oncology (2020)
331P Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA (ML) -3 and -7
Authors: M. De Laurentiis, L. de la Cruz Merino, L. Hart, A. Bardia, S-A. Im, J. Sohn, P. Neven, M. Martin, Y. Ji, S. Yang, H. Hu, A. Lteif, D. Tripathy
Journal: Annals of Oncology (2020)

RIB + endocrine therapy (ET) had a significant OS benefit vs. placebo (PBO) in pts with HR+/HER2− ABC in the ML-3 (postmenopausal pts; HR, 0.71; P = .00973; Slamon et al. N Engl J Med. 2020) and ML-7 (premenopausal pts; HR, 0.72; P = .00455; Im et al. N Engl J Med. 2019) trials. Dose reductions to manage adverse events (AEs) were allowed; prior analysis showed no impact on progression-free survival with RIB dose reduction (Beck, et al. SABCS 2018). Here we present data on RIB dose reductions and evaluate the impact on OS in ML-3 and -7. ML-3 randomized pts 2:1 to RIB or PBO (both + fulvestrant). ML-7 randomized pts 1:1 to RIB or PBO (both + ET); only pts treated with a nonsteroidal aromatase inhibitor were included in this analysis. Separate time-varying Cox regression models considering dose modifications over time were used to assess impact of dose reduction (from 600 mg) or relative dose intensity (RDI; accounts for reduction or interruption) on OS. Pooled ML-3/-7 data were analyzed to explore the relationship between pharmacokinetic RIB exposure (Ctrough) and OS. Pts by dose reduction and RDI are outlined in the table. In ML-3, HR for OS was 0.88 (95% CI, 0.64-1.21) in pts with ≥ 1 vs. 0 dose reduction, 0.98 (95% CI, 0.68-1.42) for low vs. high RDI, and 0.87 (95% CI, 0.60-1.27) for medium vs. high RDI. In ML-7, HR for OS was 0.79 (95% CI, 0.46-1.36) in pts with ≥ 1 vs. 0 dose reduction, 0.82 (95% CI, 0.44-1.52) for low vs. high RDI, and 0.88 (95% CI, 0.48-1.61) for medium vs. high RDI. Exposure-efficacy analysis suggested no clear impact of RIB exposure on OS relating to dose reductions of 400 and 200 mg.TableDose reductionRDI (%)≥ 1NoneLow1st tertileMedium2nd tertileHigh3rd tertileML-3, n (%)197 (41)286 (59)[<77.01]160 (33)[77.01-97.66]163 (34)[>97.66]160 (33)ML-7, n (%)101 (41)145 (59)[<73.43]81 (33)[73.43-97.70]84 (34)[>97.70]81 (33) Open table in a new tab RIB dose reduction does not compromise OS benefit as evidenced by the lack of relationship observed between OS and RIB dose reduction, RDI, or drug exposure. This suggests that pts starting on RIB at 600 mg who require a dose modification for AE management or other reasons do not attenuate the survival benefit.